Aenitis Champions Innovation in Bioproduction with Acoustofluidic Tech

Transforming Bioproduction with Acoustofluidic Technology

Aenitis is geared up to revolutionize the bioproduction landscape by tackling the rising demand for scalable, efficient, and precise cell processing technologies.

Pioneering Solutions with Mitis™

Mitis™, the flagship innovation from Aenitis's unique acoustofluidic technology, is already employed in diverse applications spanning research, clinical use, and industry practices. This includes various processes such as cell sorting, isolation, concentration, and washing.

Strategic Funding for Expansion

Recent funding efforts, spearheaded by the European Innovation Council Fund and including investments from Quadrivium I fund (Seventure Partners) and Mifani Invest, are set to propel commercial launch and broader global reach.

Milestone Achievement in Deeptech Sector

In a notable achievement for deeptech enterprises, Aenitis Technologies has successfully concluded its equity financing with backing from reputable entities, marking a key event in its journey toward commercializing acoustofluidic technology. This funding, acquired through a rigorous two-stage round, is aimed at propelling the company’s innovative offerings into early market stages and across international shores.

Continuing Growth and Innovation

Since its establishment, Aenitis has accumulated €14.5 million in equity funding complemented by strategic non-dilutive financial support from public bodies. This positioning makes Aenitis one of the select European entities to garner exclusive equity-based support via an EIC Accelerator initiative, reinforcing its commitment to enhancing bioproduction processes and delivering superior solutions for the fields of cell therapy and biomanufacturing.

Utilizing Investments for Technological Advancement

The investment received will facilitate preparation for Aenitis's commercial rollout, demonstrate new case studies through collaborations with key stakeholders, and establish distribution frameworks that prioritize European markets, with plans to branch into the US and select Asian regions. Additionally, these funds will aid in the final phases of technology innovations, continuing enhancements to production lines, and ensuring that Mitis™, which has already earned CE marking, is primed for market entry.

Expanded Strategic Board for Growth

Welcoming seasoned professionals to its Strategic Board, Eric Garnier, the former Vice President and General Manager of Pall Medical, will serve as the Independent Chairman and play a crucial role in boosting revenue growth while establishing vital partnerships. Michel Spagnol, representing Mifani Invest, lends his expertise and leadership experience, particularly from his time as Chairman and CEO of Novasep, strengthening Aenitis's strategic vision.

Acknowledgment of Global Significance

Svetoslava Georgieva, Chair of the EIC Fund Board, articulated the global ramifications of this investment, emphasizing its role in enhancing the European biomanufacturing landscape through Aenitis’s cutting-edge use of acoustic waves for cell manipulation.

The Future of Bioproduction

Bioproduction stands as a fundamental element in the biotech arena, enabling the streamlined creation of therapeutic cells and biologics. As industry demands rise for more cost-effective and scalable solutions, Aenitis is well-positioned to confront these challenges with its revolutionary technology. Originating from collaboration between CNRS and ESPCI Paris, the enterprise has innovated a platform harnessing acoustic levitation, allowing for gentle and non-intrusive cell manipulation at millifluidic scales, enhancing operational yields and preserving cellular integrity.

Leading the Charge in Innovative Biomanufacturing

Aenitis boasts a comprehensive patent portfolio safeguarding its technology, signifying its strong position in the global biomanufacturing sector. As the company moves forward, it focuses on optimizing production capabilities and refining its product lineup to achieve exemplary standards. With technology that promises superior recovery yields and enhanced cell quality, Aenitis addresses critical factors in scaling production while ensuring high-quality outcomes.

About AENITIS

Aenitis designs and markets unique acoustofluidic technology aimed at improving cell and gene therapy manufacturing processes. By employing sound waves for precise cell manipulation, the company boosts productivity while retaining cells' native conditions throughout the manufacturing process.

Frequently Asked Questions

What is Aenitis known for?

Aenitis is recognized for its pioneering acoustofluidic technology, which enhances cell processing efficiency and reduces costs in bioproduction.

What advantages does Mitis™ provide?

Mitis™ facilitates improved yields, reduced processing times, and greater cell viability compared to traditional cell manipulation methods.

Who are Aenitis's key investors?

Aenitis's significant investors include the European Innovation Council Fund, Quadrivium I fund, and Mifani Invest.

How does Aenitis manipulate cells?

The company employs acoustic levitation, allowing for non-invasive cell manipulation without physical contact.

What is Aenitis's market focus?

Aenitis primarily targets the biomanufacturing and cell therapy markets, aiming to set new standards for cell processing.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.